Alpha Cognition Reports Third Quarter 2026 Financial Results and Operational Update

Alpha Cognition reported that ZUNVEYL net product revenue reached $7.8 million in the third quarter of 2026, representing a 30% increase quarter-over-quarter and over 230% year-over-year. The company achieved 2,410 cumulative prescribers, exceeding its full-year 2026 goal of 2,000 a quarter early, with 1,639 quarterly prescribers representing a 22% sequential increase. Operating expenses were $13.7 million, resulting in an operating loss of approximately $6.4 million, an improvement from the $7.1 million loss reported in the second quarter of 2026. The company ended the quarter with $37.8 million in cash and cash equivalents and no debt. Management reiterated its full-year 2026 R&D and SG&A expense guidance of $50 million to $54 million.